Wang Erming

Dr. Wang Erming


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2022 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
WEWang Erming
Wang Erming
MDMariana Lemos Duarte
Mariana Lemos Duarte
LRLauren E Rothman
Lauren E Rothman
DCDongming Cai
Dongming Cai
BZBin Zhang
Bin Zhang
Neurodegenerative diseases such as Alzheimer’s disease (AD) are characterized by the progressive loss of neurons in the brain and the spinal cord. The pathophysiology of AD is multifactorial with heterogeneous molecular manifestations. The lack of efficacious therapies for AD reinforces the importance of exploring in depth multifaceted disease mechanisms. Recent progresses on AD have generated a large amount of RNA-sequencing data at both bulk and single cell levels and revealed thousands of genes with expression changes in AD. However, the upstream regulators of such gene expression changes are largely unknown. Non-coding RNAs (ncRNAs) represent the majority of the human transcriptome, and regulatory ncRNAs have been found to play an important role in regulating gene expression. A single miRNA usually targets a number of mRNAs and thus such ncRNAs are particular important for understanding disease mechanisms and developing novel therapeutics. This review aims to summarize the recent findings on the roles of ncRNAs in AD from ncRNA-omics studies with a focus on ncRNA signatures, interactions between ncRNAs and mRNAs, and ncRNA-regulated pathways in AD. We also review the potential of specific ncRNAs to serve as biomarkers and therapeutic targets for AD. In the end, we point out future directions for studying ncRNAs in AD.

1 July 1998 in Crop Science
Verified
Journal Article
Closed access
PDF file
WEWang Erming
Wang Erming
HXHongyan Xing
Hongyan Xing
YWYuxiang Wen
Yuxiang Wen
WZWenjuan Zhou
Wenjuan Zhou
RWRongxuan Wei
Rongxuan Wei
HHHu Han
Hu Han

3 January 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
WEWang Erming
Wang Erming
APAllen L. Pan
Allen L. Pan
PBPritha Bagchi
Pritha Bagchi
SRSrikant Rangaraju
Srikant Rangaraju
NSNicholas T. Seyfried
Nicholas T. Seyfried
BZBin Zhang
Bin Zhang
DUSP4 is a member of the DUSP (dual-specificity phosphatase) subfamily that is selective to the mitogen-activated protein kinases (MAPK) and has been implicated in a range of biological processes and functions in Alzheimer’s disease (AD). In this study, we utilized the stereotactic delivery of adeno-associated virus (AAV)-DUSP4 to overexpress DUSP4 in the dorsal hippocampus of 5xFAD and wildtype (WT) mice, then used mass spectrometry (MS)-based proteomics along with the label-free quantification to profile the proteome and phosphoproteome in the hippocampus. We identified protein expression and phosphorylation patterns modulated in 5xFAD mice and examined the sex-specific impact of DUSP4 overexpression on the 5xFAD proteome/phosphoproteome. In 5xFAD mice, a substantial number of proteins were up- or down-regulated in both male and female mice in comparison to age and sex-matched WT mice, many of which are involved in AD-related biological processes, such as activated immune response or suppressed synaptic activities. Many proteins in pathways, such as immune response were found to be suppressed in response to DUSP4 overexpression in male 5xFAD mice. In contrast, such a shift was absent in female mice. For the phosphoproteome, we detected an array of phosphorylation sites regulated in 5xFAD compared to WT and modulated via DUSP4 overexpression in each sex. Interestingly, 5xFAD- and DUSP4-associated phosphorylation changes occurred in opposite directions. Strikingly, both the 5xFAD- and DUSP4-associated phosphorylation changes were found to be mostly in neurons and play key roles in neuronal processes and synaptic functions. Site-centric pathway analysis revealed that both the 5xFAD- and DUSP4-associated phosphorylation sites were enriched for a number of kinase sets in females but only a limited number of sets of kinases in male mice. Taken together, our results suggest that male and female 5xFAD mice responded to DUSP4 overexpression via shared and sex-specific molecular mechanisms, which might underly similar reductions in amyloid pathology in both sexes while learning deficits were reduced in only females with DUSP4 overexpression. Finally, we validated our findings with the sex-specific AD-associated proteomes in human cohorts and further developed DUSP4-centric proteomic network models and signaling maps for each sex.

1 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
MWMinghui Wang
Minghui Wang
ALAiqun Li
Aiqun Li
MSMichiko Sekiya
Michiko Sekiya
NBNoam D. Beckmann
Noam D. Beckmann
XQXiuming Quan
Xiuming Quan
BZBin Zhang
Bin Zhang
SUMMARY: To study the molecular mechanisms driving the pathogenesis and identify novel therapeutic targets of late onset Alzheimer’s Disease (LOAD), we performed an integrative network analysis of whole-genome DNA and RNA sequencing profiling of four cortical areas, including the parahippocampal gyrus, across 364 donors spanning the full spectrum of LOAD-related cognitive and neuropathological disease severities. Our analyses revealed thousands of molecular changes and uncovered for the first-time multiple neuron specific gene subnetworks most dysregulated in LOAD. ATP6V1A , a critical subunit of vacuolar-type H + -ATPase (v-ATPase), was predicted to be a key regulator of one neuronal subnetwork and its role in disease-related processes was evaluated through CRISPR-based manipulation of human induced pluripotent stem cell derived neurons and RNAi-based knockdown in transgenic Drosophila models. This study advances our understanding of LOAD pathogenesis by providing the global landscape and detailed circuits of complex molecular interactions and regulations in several key brain regions affected by LOAD and the resulting network models provide a blueprint for developing next generation therapeutics against LOAD.

1 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
WEWang Erming
Wang Erming
MWMinghui Wang
Minghui Wang
GYGefei Yu
Gefei Yu
ATAbigail Thorpe
Abigail Thorpe
VHVahram Haroutunian
Vahram Haroutunian
BZBin Zhang
Bin Zhang
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disease that inflicts the elderly worldwide. Recent studies revealed the association of abnormal methylomic alterations in AD. However, a systematic and comprehensive study is needed to investigate the effects of methylomic changes on the molecular networks underpinning AD, in particular, in brain regions most vulnerable to AD neuropathology.Method: We profiled genome‐wide methylomic variations in the parahippocampal gyrus across 201 postmortem control, mild cognitive impaired (MCI) and AD brains in the Mount Sinai Brain Bank (MSBB) cohort. We next investigated the influence of methylomic changes on both gene and protein co‐expression networks. We then integrated the methylomic, epigenomic (ATAC‐seq), transcriptomic and proteomic data to infer the regulatory relationships among DNA methylation, chromatin accessibility, transcription and translation. Finally, we validated our key findings using an independent cohort (Religious Orders Study/Memory and Aging Project (ROSMAP)).Result: We first demonstrated the existence of significant AD‐associated variation in methylomic sites genome‐wide, which were subsequently summarized into distinct differentially methylated regions (DMRs) that are critical in AD. We then quantified the effect of the DMRs on each gene and each protein as well as gene and protein co‐expression networks. We found that DNA methylation had profound influences on not only the AD‐associated gene/protein modules but also their key regulators in the networks. With the integration of the matched multiomics data, we unveiled that DNA methylation likely influenced gene/protein expression via epigenomic peak domains in AD. Further integration of the matched bulk tissue methylation and single nucleus multiomics data revealed cell‐type specific methylomic regulation of transcriptomics in AD.Conclusion: Our study is the most extensive genome‐wide investigation on the impact of methylation on AD pathology, and the first integrative survey on the complex interactions between methylation, chromatin accessibility, and multiscale transcriptomic and proteomics networks in AD.

6 July 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
LGLei Guo
Lei Guo
NGNicholas Grimaldi
Nicholas Grimaldi
MWMinghui Wang
Minghui Wang
LHLap Ho
Lap Ho
BSBen Shackleton
Ben Shackleton
BZBin Zhang
Bin Zhang
Alzheimer’s disease (AD) is an aging-related neurodegenerative disease characterized by an initial memory impairment that progresses to a widespread cerebrocortical failure, culminating in death. Understanding the molecular mechanisms that protect brain function during aging may help reveal novel targets for the development of effective treatments for the memory and cognitive deficits associated with AD. In this study, we analyzed a gene expression dataset generated from the prefrontal cortices of individuals showing no neurological or cognitive abnormalities. The gene expression profiles were used to identify candidate protective genes. We then compared the expression patterns of these genes in aging with their expression patterns in AD, thereby enabling us to pinpoint the genes that potentially contribute to brain resilience that delays or prevents aging-related dementia. We selected seven genes that are potentially protective for aging and AD, and have known homologues in Caenorhabditis elegans (C. elegans). Among these genes, SRPK2, AAK1, EFR3A and MAPK10 were previously implicated in attenuating AD-related cognitive decline. Our experiments demonstrated that all seven genes prioritized by our resilience model significantly extended the lifespan of C. elegans. Given the important relationship between neuronal functional integrity and lifespan (i.e., lifespan vs. brain health span), this work suggests the predicted AD resilience genes could serve as important candidate targets for therapeutic intervention.